Related Experiment Video
Updated: Aug 9, 2026

Generating Genetically Modified Plasmodium berghei Sporozoites
Published on: May 5, 2023
Proteasome inhibitors block development of Plasmodium spp
S M Gantt1, J M Myung, M R Briones
1Department of Pathology, NYU Medical Center, New York, New York 10016, USA.
Abstract:
Proteasomes degrade most of the proteins inside eukaryotic cells, including transcription factors and regulators of cell cycle progression. Here we show that nanomolar concentrations of lactacystin, a specific irreversible inhibitor of the 20S proteasome, inhibit development of the exoerythrocytic and erythrocytic stages of the malaria parasite. Although lactacystin-treated Plasmodium berghei sporozoites are still invasive, their development into exoerythrocytic forms (EEF) is inhibited in vitro and in vivo. Erythrocytic schizogony of P. falciparum in vitro is also profoundly inhibited when drug treatment of the synchronized parasites is prior, but not subsequent, to the initiation of DNA synthesis, suggesting that the inhibitory effect of lactacystin is cell cycle specific. Lactacystin reduces P. berghei parasitemia in rats, but the therapeutic index is very low. Along with other studies showing that lactacystin inhibits stage-specific transformation in Trypanosoma and Entamoeba spp., these findings highlight the potential of proteasome inhibitors as drugs for the treatment of diseases caused by protozoan parasites.
Insights
Proteasome inhibitors like lactacystin can halt the development of malaria parasites, including Plasmodium falciparum. This research suggests proteasome inhibition as a potential strategy for treating protozoan parasitic diseases.
Area of Science:
- Molecular Biology
- Parasitology
- Drug Discovery
Background:
- Proteasomes are crucial for degrading proteins in eukaryotic cells, regulating vital processes like cell cycle progression.
- Protozoan parasites, responsible for diseases like malaria, possess proteasome activity essential for their lifecycle.
- Targeting essential cellular machinery in parasites offers a promising avenue for novel therapeutic development.
Purpose of the Study:
- To investigate the effect of lactacystin, a specific 20S proteasome inhibitor, on the developmental stages of the malaria parasite.
- To determine the cell cycle specificity of lactacystin's inhibitory action on Plasmodium parasites.
- To evaluate the potential of proteasome inhibitors as therapeutic agents against protozoan parasitic infections.
Main Methods:
- Treatment of Plasmodium berghei and Plasmodium falciparum with nanomolar concentrations of lactacystin.
- In vitro and in vivo assays to assess parasite development, including sporozoite invasion and exoerythrocytic form (EEF) development.
- Synchronization of erythrocytic stages and assessment of drug treatment timing relative to DNA synthesis.
- Evaluation of parasitemia reduction in infected rats.
Main Results:
- Lactacystin, at nanomolar concentrations, significantly inhibited the development of exoerythrocytic and erythrocytic stages of malaria parasites.
- Lactacystin-treated Plasmodium berghei sporozoites remained invasive but failed to develop into EEFs.
- Inhibition of Plasmodium falciparum erythrocytic schizogony was observed when drug treatment preceded DNA synthesis, indicating cell cycle specificity.
- Lactacystin reduced parasitemia in rats, but the therapeutic index was found to be very low.
Conclusions:
- Proteasome inhibition by lactacystin effectively disrupts critical developmental stages of malaria parasites.
- The cell cycle-specific inhibitory effect suggests targeted intervention points within the parasite lifecycle.
- These findings underscore the potential of proteasome inhibitors as a novel class of drugs for treating protozoan parasitic diseases, including malaria.
- Further research is warranted to optimize proteasome inhibitor-based therapies and improve their therapeutic index.
More Related Videos
Related Concept Videos
Diversity of Protists II
Malaria
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis
Anthelminthic Agents
Antiprotozoal Agents

